Glioma Diagnosis and Treatment

Gliomas are primary brain tumors arising from glial cells, with glioblastoma representing the most aggressive form and carrying a median survival of roughly fifteen months despite standard treatment combining surgical resection, radiotherapy, and the chemotherapy drug temozolomide. Advances in molecular classification have reshaped how clinicians understand and stratify these tumors: mutations in the IDH gene and methylation of the MGMT promoter, for instance, are now recognized as meaningful predictors of treatment response and patient prognosis rather than mere biological curiosities. Researchers are working to understand why glioblastoma remains so uniformly lethal despite these molecular insights, with active investigation into immunotherapy resistance, tumor heterogeneity, and the distinct biology of related tumors like medulloblastoma. A central open question is whether patient outcomes can be meaningfully improved by matching treatment more precisely to a tumor's genetic profile, or whether the blood-brain barrier and the brain's immunosuppressive environment will continue to limit what systemic therapies can achieve.

Works

155,136

Total citations

2,436,576

Keywords

GlioblastomaTemozolomideIDH MutationRadiotherapyMolecular ClassificationMGMT Promoter Methylation